DALLAS, Aug. 10, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring CEL-SCI Corp. (NYSE Amex:CVM). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on CEL-SCI Corp. (NYSE Amex:CVM) should be of particular interest to other biotechnology companies: Introgen Therapeutics Inc. (Pink Sheets:INGNQ), Targeted Genetics Corp. (Nasdaq:TGEN), Vical Inc. (Nasdaq:VICL) and Immunogen Inc. (Nasdaq:IMGN).
It is available at: http://www.beaconequity.com/i/CVM/
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
CEL-SCI Corp. (NYSE Amex:CVM) is a developer, manufacturer and marketer of novel therapies through proprietary anti-cancer technologies to fight cancer and heteroconjugate technologies referred to as Ligand Epitope Antigen Presentation System (L.E.A.P.S.) for the treatment of bacterial, viral and parasitic infections. The Company's flagship drug therapy, Multikine, is a new cancer immunotherapy drug developed to stimulate the human body's own immune system to fight and kill cancer cells.
In the report, the analyst notes:
"The Company's flagship drug therapy, Multikine, is a new cancer immunotherapy drug developed to stimulate the human body's own immune system to fight and kill cancer cells. Multikine has cleared phase II drug trial and moved into phase III in the United States and Canada to treat advanced primary head and neck cancer patients. The Company also focuses its efforts on the improvement of immunotherapies to prevent/treatment of avian flu, H1N1, herpes simplex, malaria, viral encephalitis, smallpox, vaccinia and other infections.
"The Company has received recent media and investor attention due to official responses to the rapid spread of the H1N1 virus reported by the World Health Organization (WHO), which recently elevated its warning to world pandemic level six by Dr. Margaret Chan, director-general of WHO, on June 11, 2009. Additional investor interest followed the Company's announcement that the goal of its experimental H1N1 drug candidate Cel-1000 is not only to combat the current strain but future mutations of the strain as well."
To read the entire report visit: http://www.beaconequity.com/i/CVM
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon, please visit http://www.BeaconEquity.com
BeaconEquity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions and information free of charge exclusively to individuals who wish to receive them.